<clinical_study>
  <!-- This xml conforms to an XML Schema at:
    https://clinicaltrials.gov/ct2/html/images/info/public.xsd -->
  <required_header>
    <download_date>ClinicalTrials.gov processed this data on November 19, 2021</download_date>
    <link_text>Link to the current ClinicalTrials.gov record.</link_text>
    <url>https://clinicaltrials.gov/show/NCT04751539</url>
  </required_header>
  <id_info>
    <org_study_id>BB-AND017AU001</org_study_id>
    <nct_id>NCT04751539</nct_id>
  </id_info>
  <brief_title>A Dose-escalation Study of AND017 in Healthy Subjects</brief_title>
  <official_title>A Randomized, Double-Blind, Placebo-Controlled Dose-Escalation Study in Healthy Subjects to Evaluate the Safety, Tolerability, Pharmacokinetics and Pharmacodynamics of AND017 Following Oral Single and Multiple Dose Administration</official_title>
  <sponsors>
    <lead_sponsor>
      <agency>Kind Pharmaceuticals LLC</agency>
      <agency_class>Industry</agency_class>
    </lead_sponsor>
  </sponsors>
  <source>Kind Pharmaceuticals LLC</source>
  <oversight_info>
    <is_fda_regulated_drug>No</is_fda_regulated_drug>
    <is_fda_regulated_device>No</is_fda_regulated_device>
  </oversight_info>
  <brief_summary>
    <textblock>
      This is a phase I, randomized, double-blind, placebo-controlled, dose-escalation study in&#xD;
      healthy subjects to evaluate safety, tolerability, PKs and PDs of AND017 following oral&#xD;
      single and multiple dose administration.&#xD;
    </textblock>
  </brief_summary>
  <overall_status>Completed</overall_status>
  <start_date type="Actual">July 16, 2018</start_date>
  <completion_date type="Actual">February 11, 2019</completion_date>
  <primary_completion_date type="Actual">February 11, 2019</primary_completion_date>
  <phase>Phase 1</phase>
  <study_type>Interventional</study_type>
  <has_expanded_access>No</has_expanded_access>
  <study_design_info>
    <allocation>Randomized</allocation>
    <intervention_model>Sequential Assignment</intervention_model>
    <primary_purpose>Treatment</primary_purpose>
    <masking>Quadruple (Participant, Care Provider, Investigator, Outcomes Assessor)</masking>
  </study_design_info>
  <primary_outcome>
    <measure>Safety evaluations</measure>
    <time_frame>17 Days</time_frame>
    <description>Incidents of AE and abnormal laboratory tests</description>
  </primary_outcome>
  <secondary_outcome>
    <measure>Plasma Cmax of AND017</measure>
    <time_frame>1 day</time_frame>
    <description>The plasma Cmax of AND017 by single dose administration</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Plasma Tmax of AND017</measure>
    <time_frame>1 day and 10 days</time_frame>
    <description>The plasma Tmax of AND017 after single dose administration on D1 and multiple doses for 10 consecutive days on D10</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Plasma t1/2 of AND017</measure>
    <time_frame>1 day and 10 days</time_frame>
    <description>The plasma T1/2 of AND017 after single dose administration on D1 and multiple doses for 10 consecutive days on D10</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Plasma AUC of AND017</measure>
    <time_frame>1 day and 10 days</time_frame>
    <description>The plasma AUCs of AND017 after single dose administration on D1 and multiple doses for 10 consecutive days on D10</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Plasma CL/F of AND017</measure>
    <time_frame>1 day</time_frame>
    <description>The plasma CL/F of AND017 after single dose administration</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Plasma Vz/F of AND017</measure>
    <time_frame>1 day</time_frame>
    <description>The plasma Vz/F of AND017 after single dose administration</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Plasma MRT of AND017</measure>
    <time_frame>1 day</time_frame>
    <description>The plasma MRT of AND017 after single dose administration</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Plasma λz of AND017</measure>
    <time_frame>1 day</time_frame>
    <description>The plasma λz of AND017 after single dose administration</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Plasma %AUCex of AND017</measure>
    <time_frame>1 day</time_frame>
    <description>The plasma %AUCex of AND017 after single dose administration</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Plasma Css,min of AND017</measure>
    <time_frame>10 days</time_frame>
    <description>The plasma Css,min of AND017 by multiple administration for 10 consecutive days</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Plasma Css,max of AND017</measure>
    <time_frame>10 days</time_frame>
    <description>The plasma Css,max of AND017 by multiple administration for 10 consecutive days</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Plasma Css,avg of AND017</measure>
    <time_frame>10 days</time_frame>
    <description>The plasma Css,avg of AND017 by multiple administration for 10 consecutive days</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Plasma CLss/F of AND017</measure>
    <time_frame>10 days</time_frame>
    <description>The plasma CLss/F of AND017 by multiple administration for 10 consecutive days</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Plasma Vss/F of AND017</measure>
    <time_frame>10 days</time_frame>
    <description>The plasma Vss/F of AND017 by multiple administration for 10 consecutive days</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Plasma Rac(AUC) of AND017</measure>
    <time_frame>10 days</time_frame>
    <description>The plasma Rac(AUC) of AND017 by multiple administration for 10 consecutive days</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Plasma DF of AND017</measure>
    <time_frame>10 days</time_frame>
    <description>The plasma DF of AND017 by multiple administration for 10 consecutive days</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>PD parameters</measure>
    <time_frame>17 days</time_frame>
    <description>Change from baseline levels of EPO</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>PD parameters</measure>
    <time_frame>17 days</time_frame>
    <description>Change from baseline levels of HB</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>PD parameters</measure>
    <time_frame>17 days</time_frame>
    <description>Change from baseline levels of RET</description>
  </secondary_outcome>
  <number_of_arms>3</number_of_arms>
  <enrollment type="Actual">78</enrollment>
  <condition>Healthy Volunteers</condition>
  <arm_group>
    <arm_group_label>AND017 single dose escalation</arm_group_label>
    <arm_group_type>Experimental</arm_group_type>
    <description>Subjects will be administrated with single dose of AND017 capsule from 1 mg to 50 mg during Part A.</description>
  </arm_group>
  <arm_group>
    <arm_group_label>AND017 repeated dose escalation</arm_group_label>
    <arm_group_type>Placebo Comparator</arm_group_type>
    <description>Subjects will be administrated with repeated dose of AND017 from 4 mg to 30 mg for 10 consecutive days during Part B.</description>
  </arm_group>
  <arm_group>
    <arm_group_label>Placebo</arm_group_label>
    <arm_group_type>Placebo Comparator</arm_group_type>
    <description>Placebo administrated once on Day 1 in Part A or daily from Day 1 to Day 10 in Part B</description>
  </arm_group>
  <intervention>
    <intervention_type>Drug</intervention_type>
    <intervention_name>AND017 single dose</intervention_name>
    <description>AND017 administrated as oral single-dose on Day 1 in Part A</description>
    <arm_group_label>AND017 single dose escalation</arm_group_label>
  </intervention>
  <intervention>
    <intervention_type>Drug</intervention_type>
    <intervention_name>AND017 multiple dose</intervention_name>
    <description>AND017 administrated once daily from Day 1 to Day 10 in Part B</description>
    <arm_group_label>AND017 repeated dose escalation</arm_group_label>
  </intervention>
  <intervention>
    <intervention_type>Drug</intervention_type>
    <intervention_name>Placebo</intervention_name>
    <description>Placebo administrated once on Day 1 in Part A or daily from Day 1 to Day 10 in Part B</description>
    <arm_group_label>Placebo</arm_group_label>
  </intervention>
  <eligibility>
    <criteria>
      <textblock>
        Inclusion Criteria:&#xD;
&#xD;
          1. BMI within 18.0-30.0 kg/m2 (inclusive)&#xD;
&#xD;
          2. Blood Pressure (BP) and 12-lead electrocardiogram (ECG) showing no clinically&#xD;
             significant abnormalities during screening;&#xD;
&#xD;
          3. No clinically significant abnormal values in physical examination, clinical laboratory&#xD;
             tests, liver function or kidney function;&#xD;
&#xD;
        Exclusion Criteria:&#xD;
&#xD;
          1. Current or chronic history of liver disease or known hepatic or biliary abnormalities,&#xD;
             including but not limited to ALT, alkaline phosphatase and bilirubin &gt;1.5xULN&#xD;
             (isolated bilirubin&gt;1.5xULN is acceptable if bilirubin is fractionated and direct&#xD;
             bilirubin &lt;35%);&#xD;
&#xD;
          2. Subjects with Hb: male &lt;120 g/L or &gt;160 g/L, female &lt;110 g/L or &gt;150 g/L;&#xD;
&#xD;
          3. Subjects with any abnormalities of hematology during screening: Mean corpuscular&#xD;
             volume (MCV), platelet count, serum iron, ferritin;&#xD;
&#xD;
          4. Subjects with a history of medical treatment or disease likely to increase the risk of&#xD;
             bleeding or disturbance of blood coagulation;&#xD;
&#xD;
          5. History of deep vein thrombosis, stoke, transient ischemic attack, pulmonary embolism&#xD;
             or other thrombosis-related condition within the last five years;&#xD;
&#xD;
          6. History of myocardial infarction, heart failure or acute coronary syndrome;&#xD;
&#xD;
          7. Evidence of active peptic, duodenal or esophageal ulcer disease at screening;&#xD;
&#xD;
          8. History of pulmonary artery hypertension;&#xD;
&#xD;
          9. History of sensitivity to heparin or heparin-induced thrombocytopenia;&#xD;
&#xD;
         10. Subjects with major illness or surgery within past 3 months prior to screening, or&#xD;
             planned surgery during study;&#xD;
&#xD;
         11. Known or suspected history of drug abuse within the past 5 years or presence of drug&#xD;
             abuse within 3 months before study;&#xD;
&#xD;
         12. Donated blood &gt;400 mL or significant blood loss equivalent to 400 mL or received blood&#xD;
             transfusion within 3months of screening; or donated blood &gt;200 mL or significant blood&#xD;
             loss equivalent to 200 mL within 1 month prior to screening.&#xD;
&#xD;
         13. Participation in any clinical study with an investigational drug, biologic or device&#xD;
             within 4 weeks or 5 times the half-life of the specific drug/biologics (whichever is&#xD;
             longer), prior to dosing;&#xD;
      </textblock>
    </criteria>
    <gender>All</gender>
    <minimum_age>18 Years</minimum_age>
    <maximum_age>45 Years</maximum_age>
    <healthy_volunteers>Accepts Healthy Volunteers</healthy_volunteers>
  </eligibility>
  <overall_official>
    <last_name>Yusha Zhu, MD PhD</last_name>
    <role>Study Director</role>
    <affiliation>Kind Pharmaceuticals LLC</affiliation>
  </overall_official>
  <location>
    <facility>
      <name>Scientia Clinical Research</name>
      <address>
        <city>Randwick</city>
        <state>New South Wales</state>
        <zip>2031</zip>
        <country>Australia</country>
      </address>
    </facility>
  </location>
  <location_countries>
    <country>Australia</country>
  </location_countries>
  <verification_date>May 2021</verification_date>
  <study_first_submitted>January 28, 2021</study_first_submitted>
  <study_first_submitted_qc>February 8, 2021</study_first_submitted_qc>
  <study_first_posted type="Actual">February 12, 2021</study_first_posted>
  <last_update_submitted>May 7, 2021</last_update_submitted>
  <last_update_submitted_qc>May 7, 2021</last_update_submitted_qc>
  <last_update_posted type="Actual">May 11, 2021</last_update_posted>
  <responsible_party>
    <responsible_party_type>Sponsor</responsible_party_type>
  </responsible_party>
  <patient_data>
    <sharing_ipd>No</sharing_ipd>
  </patient_data>
  <!-- Results have not yet been posted for this study                                          -->
</clinical_study>

